The Target-Exclusive Launch Pairs Bright Berry Flavor With GORGIE's Clean, Functional Formula

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- GORGIE, the modern energy drink redefining the category with clean ingredients and no artificial sweeteners, announced today the launch of Berry Burst, a bold new flavor inspired by the juicy berry taste consumers know and love.

Berry Burst is juicy, craveable, and playful — a refreshing take on a classic favorite, reimagined for today's wellness-minded consumer.

Known for blending function with flavor, GORGIE created Berry Burst to deliver an energizing boost without sacrificing ingredient quality, taste, or aesthetic. Each can contains 150mg of green tea caffeine alongside functional ingredients including Biotin, B Vitamins, and L-Theanine. With zero grams of sugar, five calories, and no artificial sweeteners, Berry Burst delivers the functional energy GORGIE fans love.

Wrapped in the rich purple tones defining this fall season, the new flavor is designed to look just as good in your hand as it tastes in every sip.

"Berry is having a moment, and we wanted to give her the full GORGIE treatment," said Michelle Cordeiro Grant, Founder and CEO of GORGIE. "Berry Burst started with the idea that your drink can double as your best accessory. Purple is having its it-girl moment this fall, and this flavor feels bright, bold, polished, and a little unexpected. Whether you are running to a meeting, heading to a workout, getting ready for Fashion Week, or making late-night plans, Berry Burst was created to bring feel-good energy to every part of your day."

Inspired by the rich hues of fall and the idea that a drink can double as the perfect accessory, GORGIE took Berry Burst to the streets of New York City for its debut campaign. Styled alongside leather, fall jackets, and polished seasonal looks, Berry Burst felt perfectly at home bringing a little Fashion Week energy to the beverage aisle.

The launch arrives during a period of significant retail growth for GORGIE, which now has nearly 60,000 points of distribution in the marketplace and is on track to reach 100,000 in early 2027.

"Consumers are showing us that modern energy is not a niche. It is the next evolution of the category," added Cordeiro Grant. "They want ingredients they recognize, benefits that support their days, flavors they genuinely crave, and a can they are excited to carry. Berry Burst brings all of that together!"

Berry Burst will be available exclusively at Target locations nationwide beginning September 13th.

About GORGIE:

GORGIE is the fastest-growing modern energy brand in the United States, redefining the category with better-for-you ingredients, functional benefits, and a community-driven approach where energy meets wellness. Each can features 150mg of green tea caffeine alongside wellness-supporting ingredients including Biotin, B Vitamins, and L-Theanine, delivering smooth, sustained energy without the jitters or crash. GORGIE is vegan, gluten-free, and free from artificial sweeteners, including aspartame, sucralose, and erythritol.

Built on the mission to create a more elevated alternative within the energy space, GORGIE blends taste, function, beauty, and culture in a way that resonates with today's modern wellness consumer. Built community-first, GORGIE has evolved beyond a beverage brand into Club GORGIE, the brand's members-only app experience offering exclusive access to product drops, events, rewards, and insider experiences for its highly engaged community.

Founded by Michelle Cordeiro Grant in 2022, GORGIE officially launched its first line of sparkling energy drinks in January 2023. The company is backed by Notable Capital and Coefficient Capital, along with other strategic partners. GORGIE has quickly become one of the fastest-growing natural energy drink brands in the country. Retail sales are up 600% year over year, GORGIE is available in more than 15,000 stores I think this is doors, but if they are counted as the same thing, then this is okay nationwide, and it is the No. 1 independent energy drink brand at Targetyes. At a leading national natural retailer, GORGIE now holds nearly 20% of the energy category, almost tripling its share from approximately 7% one year ago. yes

GORGIE is available direct-to-consumer on GETGORGIE.COM and Amazon, as well as in thousands of retail locations nationwide. GORGIE is a community, a brand, and a platform on a mission to make wellness fun, with products that support energy for all-day, everyday life.

For more information, visit getgorgie.com and follow @getgorgie on Instagram and TikTok.

Media Contact

Amanda Bosco, [email protected]

SOURCE GORGIE

Share this article

Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer

MRI surveillance without prophylactic cranial irradiation improved cognitive failure-free survival and substantially reduced serious treatment-related adverse events

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

For decades, PCI has been used after initial therapy for SCLC because studies conducted before routine MRI demonstrated that it reduced brain metastases and improved overall survival. MAVERICK was designed to determine whether modern MRI surveillance could allow patients to avoid PCI—and its potential cognitive and other toxicities—without compromising survival.

The trial enrolled 304 patients with limited-stage or extensive-stage SCLC between January 2020 and December 2025. All participants had completed initial therapy and had no brain metastases on MRI before enrollment. Patients were randomly assigned to MRI surveillance alone or MRI surveillance plus PCI (25 Gy in 10 fractions). In both groups, brain MRIs were performed every three months during the first year and every six months during the second year, with cognitive testing conducted at the same intervals. The study's cognitive assessments included the Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association and Trail Making Test.

At a median follow up of 22 months among living patients, MRI surveillance alone significantly improved cognitive failure-free survival, the trial's primary endpoint, reducing the risk of cognitive failure or death by 40% compared with MRI plus PCI (HR 0.60; 90% CI 0.46–0.78; p=0.001). The benefit was similar among patients with limited-stage and extensive-stage disease and regardless of whether patients received immunotherapy.

A preliminary overall survival analysis, conducted after 128 deaths, showed no apparent difference between the treatment strategies (HR for the MRI alone arm, 0.90; 90% CI 0.67–1.20). The final overall survival analysis is planned after 190 deaths. Brain metastasis-free survival also was not significantly different between the two groups (HR 1.25; 90% CI 0.95–1.66).

Serious treatment-related adverse events were less frequent with MRI surveillance alone. Grade 3–5 adverse events occurred in 0.8% of patients receiving MRI surveillance alone compared with 7.9% of those receiving MRI plus PCI (p=0.004). One grade 5 encephalopathy event occurred in the MRI plus PCI group.

"MRI surveillance alone was associated with improved cognitive failure-free survival compared to a strategy of MRI surveillance plus PCI. The benefit of MRI surveillance alone also appears to be consistent across patients with both limited-stage and extensive-stage small-cell lung cancer," said Chad Rusthoven, MD, of the University of Colorado School of Medicine and the study presenter. "These results support MRI surveillance alone as the standard of care for patients with SCLC."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer

Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved

progression-free survival and response rates

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Relapsed SCLC remains a highly aggressive disease with limited effective treatment options and poor outcomes following first-line immunotherapy and platinum-based chemotherapy. Topotecan has long been a standard second-line treatment, but its survival benefit remains modest. TAISHAN-302 evaluated Tam-Peli as a second-line treatment for patients whose SCLC had relapsed after first-line therapy.

The randomized, open-label study enrolled 451 patients, with 225 assigned to Tam-Peli and 226 to topotecan. Patients receiving Tam-Peli were treated with 2.0 mg/kg intravenously on day 1 of each three-week cycle, with a maximum dose of 200 mg. Treatment continued until disease progression or unacceptable toxicity. The study's primary endpoint was overall survival, with progression-free survival and objective response rate as key secondary endpoints.

As of May 20, 2026, after a median follow-up of 9.4 months, median overall survival was 13.3 months with Tam-Peli compared with 9.4 months with topotecan. Tam-Peli reduced the risk of death by 54% (HR 0.46; 95% CI 0.35–0.62; p0.0001). The survival benefit was consistent across prespecified subgroups, including patients with brain metastases, liver metastases and a chemotherapy-free interval of less than 90 days.

Tam-Peli also significantly improved progression-free survival. Median progression-free survival was 7.4 months with Tam-Peli versus 2.8 months with topotecan, representing a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI 0.23–0.37; p0.0001). The objective response rate was 59.1% with Tam-Peli compared with 9.7% with topotecan (p0.0001).

The safety profile of Tam-Peli was considered manageable and consistent with its known profile, with no new safety signals identified. Grade 3 or higher treatment-related adverse events occurred in 46.4% of patients receiving Tam-Peli compared with 74.7% receiving topotecan, and there were no treatment-related deaths in the Tam-Peli arm. Treatment-emergent interstitial lung disease or pneumonitis occurred in 4.9% of patients receiving Tam-Peli and 1.4% receiving topotecan; grade 3 events occurred in 0.9% of patients in each group, with no grade 4 or 5 events reported.

"TAISHAN-302 is among the first phase III studies of an antibody-drug conjugate to demonstrate statistically significant and clinically meaningful improvements in overall survival, progression-free survival and objective response rate compared with topotecan in relapsed small-cell lung cancer," said Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China. "Together with a generally favorable and manageable safety profile, these results support Tam-Peli as a potential new standard-of-care option for second-line SCLC and may reshape the treatment landscape for this challenging disease."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer

B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan

and improved progression-free survival and response rates

SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. The findings were presented today at the IASLC 2026 World Conference on Lung Cancer (WCLC).

ARTEMIS-008 (NCT06498479) is a multicenter, open-label, randomized Phase III study. A total of 461 patients in China were randomized 1:1 to receive Ris-Rez 8.0 mg/kg every three weeks or topotecan 1.2 mg/m² on days 1 through 5 every three weeks. More than 80% of patients had previously received PD-(L)1 inhibitors. The primary endpoint was overall survival, with progression-free survival, objective response rate, disease control rate and safety among the key secondary endpoints.

At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, median overall survival was 18.5 months with Ris-Rez compared with 10.3 months with topotecan. Ris-Rez reduced the risk of death by 54% (HR 0.46; 95% CI, 0.35–0.62; P0.0001), with consistent overall survival benefits across relevant subgroups.

Blinded independent central review also favored Ris-Rez across key secondary efficacy measures. Median progression-free survival was 7.2 months with Ris-Rez versus 3.0 months with topotecan (HR 0.33; 95% CI, 0.25–0.42). The objective response rate was 58.3% versus 12.6%, respectively, and the disease control rate was 90.4% versus 60.2%. Investigator-assessed outcomes were consistent with the central review findings.

Grade 3 or higher treatment-related adverse events occurred less frequently with Ris-Rez than with topotecan, at 60.9% versus 78.2%. The most common grade 3 or higher treatment-related adverse events were hematologic toxicities, including decreased neutrophil count, decreased white blood cell count, anemia, decreased lymphocyte count and decreased platelet count.

"Ris-Rez demonstrated a statistically significant and clinically meaningful overall survival benefit over topotecan in patients with SCLC that progressed after platinum-based therapy, with a favorable safety profile," said Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China.

"These results suggest the potential of Ris-Rez to define a new standard of care in relapsed SCLC."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC

Phase 3 EVOKE-03/KEYNOTE-D46 reports numerically longer progression-free survival and higher response rates, but no statistically significant PFS or OS benefit

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

In the study, median progression-free survival (PFS) by blinded independent central review was 11.8 months with SG plus pembrolizumab compared with 7.7 months with pembrolizumab alone (HR, 0.81; 95% CI, 0.66-1.00; P=0.0252). Although PFS was numerically longer with the combination, the result did not meet the prespecified threshold for statistical significance. At the interim analysis, median overall survival was 21.5 months with SG plus pembrolizumab and 22.8 months with pembrolizumab alone (HR, 1.07; 95% CI, 0.85-1.35; P=0.7155).

"While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary PFS endpoint, and overall survival was not significantly improved at this interim analysis," said Giannis Mountzios, M.D., of the Henry Dunant Hospital Center, Athens, Greece. "These findings provide important information as we continue to evaluate treatment strategies for patients with PD-L1-high metastatic NSCLC."

EVOKE-03/KEYNOTE-D46 is an open-label Phase 3 study that enrolled 620 patients with previously untreated metastatic NSCLC, PD-L1 TPS of at least 50%, and no EGFR, ALK or ROS1 alterations. Participants were randomized to receive SG at 10 mg/kg intravenously on days 1 and 8 plus pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle, or pembrolizumab alone. The dual primary endpoints were PFS by blinded independent central review and overall survival.

The confirmed objective response rate was higher with SG plus pembrolizumab than with pembrolizumab alone. The abstract reports an objective response rate of 55.6% for the combination and 43.7% for pembrolizumab alone. The disease control rate reported in the study table was 83.3% versus 73.1%, respectively, and median duration of response was 21.4 months versus 21.3 months.

Treatment-related adverse events occurred in 93.2% of patients receiving SG plus pembrolizumab and 65.4% of those receiving pembrolizumab alone. Grade 3 or higher treatment-related adverse events occurred in 55.7% and 16.5% of patients, respectively. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea. The safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed with the combination.

Dr. Mountzios concluded that, despite a numerical improvement in PFS and a higher response rate, SG plus pembrolizumab did not meet statistical significance for PFS compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic NSCLC Overall survival also did not meet statistical significance at the interim analysis.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rackspace Technology, Inc. (NASDAQ: RXT) between May 7, 2026 and July 8, 2026 inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.

So what: If you purchased Rackspace securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Rackspace class action, go to https://rosenlegal.com/cases/rackspace-technology-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rackspace's enterprise AI efforts would require Rackspace to significantly re-prioritize its capacity and capital away from the profitable Private Cloud segment; (2) Rackspace's Public Cloud revenue was declining as customers contracted directly with hyperscale cloud platforms; (3) as a result, Rackspace was likely to significantly reduce a material portion of its Public Cloud infrastructure resale business; (4) as a result, Rackspace's fiscal year 2026 revenue would be significantly impacted; and (5) as a result of the foregoing, defendants' public statements about Rackspace's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Rackspace class action, go to https://rosenlegal.com/cases/rackspace-technology-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

Helen Woodward Animal Center's Surf Dog Surf-a-Thon was a first-of-its-kind event that transformed the irresistible sight of dogs on surfboards into a powerful force for good. What began as a celebration of canine courage and surf skills has grown into a beloved tradition that raises life-saving funds for orphan pets — while proving, year after year, that "man's best friend" is capable of truly phenomenal things. 

Hoping to earn a coveted spot among the "Top Surf Dogs," canine competitors will hit the waves in 10-minute heats, showing off their surfing skills before a panel of surf pros and passionate aficionados. Judges will score each furry competitor on ride length, wave technique, enthusiasm and, of course, confidence on the board. First-, second- and third-place winners will be crowned in each weight class, with the top dogs advancing to the ultimate showdown: the Best-In-Surf finals!  

The day will also unleash a separate Freestyle Surf Contest, where creativity takes center stage and almost anything goes on the waves. Two crowd-favorite categories are back: Duos & Trios, featuring two — and sometimes even three — dogs sharing a single surfboard, and the Peeps & Pups Tandem Competition, where four-legged surfers and their favorite humans team up to ride the waves together.

There's more in store for the whole family, with a full lineup of beachside activities and entertainment including a special ceremony honoring Surf Dog legends Sugar, Faith and Delilah, and the highly anticipated awards ceremony — where the day's top four-legged stars will take home their well-earned honors.  

What makes Helen Woodward Animal Center's Surf Dog Surf-a-Thon truly special is that every wave ridden helps create a second chance for an orphan pet. With all proceeds supporting Helen Woodward Animal Center's lifesaving work, the event gives surfing and fundraising pooches the chance to win prizes while making an incredible difference.

Portions of today's Surf Dog Surf-A-Thon competition (including the "Best in Surf" Heat at 12:00 PM PST) will be streamed live on https://www.facebook.com/surfdogsurfathon/.

For more information on Helen Woodward Animal Center's Surf Dog Surf-A-Thon, visit https://animalcenter.org/surf-dog-surf-a-thon/ or call 858-756-4117.

About Helen Woodward Animal Center

Helen Woodward Animal Center is a private, non-profit organization where "people help animals and animals help people." Founded in 1972 in Rancho Santa Fe, Calif., the Center provides services for more than 90,000 people and more than 10,000 animals annually through adoptions, educational and therapeutic programs both onsite and throughout the community. For more information, go to:  www.animalcenter.org.

SOURCE Helen Woodward Animal Center

Share this article

Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). The study evaluated the company's first-in-class next-generation immuno-oncology therapy, ivonescimab, versus pembrolizumab as first-line treatment for patients with PD-L1-positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC).

The findings were selected as a Late-Breaking Abstract (LBA) for oral presentation and included in the official WCLC press program.

On September 13, the WCLC official website published the Abstract data on overall survival (OS) from the HARMONi-2 study. On September 15, Professor Caicun Zhou, Principal Investigator of HARMONi-2, IASLC President, and Director of the Department of Oncology at Shanghai East Hospital, will deliver the formal oral presentation (Oral) at the conference, sharing the complete results of the HARMONi-2 study with the global industry.

As of the data cutoff on August 20, 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming spending function was used, with a one-sided alpha of 0.0141.

Results showed that, compared with pembrolizumab, first-line treatment with ivonescimab significantly prolonged OS in patients with PD-L1-positive advanced NSCLC. This finding met the prespecified statistical significance threshold and demonstrated clear clinical benefit. The overall survival benefit was generally consistent across prespecified subgroups, with particularly pronounced benefit observed in the PD-L1-high population.

1. Intention-to-Treat (ITT) Population: Median OS of 30.8 Months with Ivonescimab, 27% Reduction in Risk of Death

- In the ITT population, ivonescimab monotherapy significantly prolonged OS versus pembrolizumab, with median OS of 30.8 months versus 22.6 months (HR=0.73; 95% CI: 0.57–0.95; P=0.009), corresponding to a 27% reduction in the risk of death.

2. Overcoming Traditional Anti-VEGF Treatment Contraindications: No Significant Increase in Bleeding Risk Observed in High-Risk Squamous Patients

Squamous NSCLC patients accounted for 45.5% of the HARMONi-2 population, and non-squamous patients for 54.5%. Among squamous patients treated with ivonescimab, 72.2% had central tumors, 10.0% had tumor cavitation or necrosis, and 6.7% had tumors encasing major vessels.

These populations are traditionally considered contraindicated or high-risk for anti-VEGF therapies and have long lacked effective treatment options. However, no apparent increase in bleeding risk was observed with ivonescimab, and these patients showed favorable benefit.

3. Consistent OS Benefit with Ivonescimab Regardless of PD-L1 Expression Level, with Particularly Pronounced Benefit in the TPS ≥50% Population

- In the PD-L1 TPS ≥50% subgroup, OS HR=0.58 (95% CI: 0.38–0.89), corresponding to a 42% reduction in the risk of death.

- In the PD-L1 TPS 1–49% subgroup, OS HR=0.85 (95% CI: 0.61–1.18), corresponding to a 15% relative reduction in the risk of death.

4. Consistent OS Benefit with Ivonescimab Regardless of Histology (Squamous and Non-Squamous)

- In the squamous cell carcinoma subgroup, OS HR=0.65 (95% CI: 0.45–0.95), corresponding to a 35% reduction in the risk of death.

- In the non-squamous subgroup, OS HR=0.79 (95% CI: 0.55–1.14), corresponding to a 21% reduction in the risk of death.

5. Favorable Overall Safety Profile with No New Safety Signals; Safety Characteristics Generally Consistent Between Arms

In May 2024, a prespecified interim analysis of progression-free survival (PFS) assessed by the Independent Data Monitoring Committee (IDMC) confirmed that HARMONi-2 met its primary PFS endpoint with statistically significant and clinically meaningful results. Median PFS was 11.14 months with ivonescimab versus 5.82 months with pembrolizumab (HR=0.51, P0.0001). This indication was approved in China in 2025.

HARMONi-2 is the first randomized, double-blind, controlled Phase III clinical study to demonstrate statistically significant positive OS and PFS results versus pembrolizumab.

An international multicenter Phase III clinical study evaluating ivonescimab monotherapy versus pembrolizumab as first-line treatment for PD-L1-high NSCLC (HARMONi-7/AK112-3007) is currently progressing efficiently.

To date, ivonescimab has consistently achieved dual-positive OS and PFS results across multiple Phase III head-to-head trials against PD-1/L1 therapies and continues to expand into major solid tumors beyond lung cancer. The synergistic antitumor effects of ivonescimab's dual "immuno-oncology + anti-angiogenesis" mechanism continue to be validated in both clinical research and real-world settings. Ivonescimab has the potential to provide a more effective treatment option with a manageable safety profile for cancer patients worldwide and to drive continued progress in oncology care.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

Share this article

The Wellness Room is part of a broader initiative between RBC and Conscientia Health that includes a wellness curriculum focused on mental health awareness, resilience, and coping strategies; educational programming workshops; and expanded support pathways for students and families. 

"This is about creating a culture where wellness is foundational to student success," said Nicole Wall, RBC Student Assistance Counselor. "As RBC continues to expand opportunities and strengthen student support systems, we remain committed to exceeding the needs of the whole child academically, spiritually, and emotionally." 

"We didn't choose today's date, the timing found us," said Dr. Simbiat Adighije (Dr. Sim), Founder of Conscientia Health, who has led the partnership. "But it's a reminder of why this work matters. Too many young people carry real struggles quietly, and too many adults around them don't know until it's a crisis. This room is one answer to that: a place where a student can be seen and supported before things reach that point. We're proud to build that alongside Red Bank Catholic." 

The Wellness Room includes a private consultation space, a group and workshop area for peer support sessions, and a self-guided check-in tool connecting students directly with a clinician when needed. The initiative is part of RISE by Conscientia, a program extending Conscientia's integrated care model into school communities. 

About Red Bank Catholic High School 

Red Bank Catholic is a vibrant, beloved, Catholic co-educational institution with a storied history, an extraordinary spirit, and a record of achievement in the classroom and beyond. Our programs pursue excellence in faith, academics, cultural awareness, athletics, and personal wellness in a mission to fully engage the minds, hearts, and souls of students in our Roman Catholic community so that they can succeed in every aspect of their lives. 

About Conscientia Health 

Conscientia Health is a telehealth provider offering integrated psychiatry, therapy, and primary care, with a mission to make whole-person care accessible and coordinated. Conscientia operates over 20 physical locations across New Jersey, providing hybrid in-person and virtual care. 

Conscientia Health's R.I.S.E. Teen Mental Health Program supports adolescents ages 12 to 19 through personalized teen mental health services for emotional, behavioral, and mental health challenges. We help teenagers reclaim their inner strength, develop practical life skills, and build resilience through integrated behavioral health and primary care support.

SOURCE Conscientia Health; Red Bank Catholic High School

Share this article

BRICS countries rally to counter shocks of power politics, unilateralism: China Daily editorial

BEIJING, Sept. 12, 2026 /PRNewswire/ -- The following article was published today by China Daily.

The 18th BRICS Summit, which opened on Saturday in New Delhi, the capital of India, is an opportunity for the participating countries to build consensus on development through strategic communication, improve the quality of development through practical cooperation, resolve differences through dialogue and consultation, and address risks and challenges through solidarity and collaboration.

This year marks the 20th anniversary of BRICS cooperation. Over the past two decades, the BRICS cooperation mechanism has become the world's most influential platform for cooperation among emerging markets and developing countries.

In his speech at Session I of the summit, President Xi Jinping reviewed the development of BRICS cooperation over the past two decades, underscoring that it has been 20 years of self-reliance and self-strengthening, with the member countries standing together through thick and thin and engaging in fruitful cooperation.

This has helped safeguard the common interests of the Global South, provided the world with stability and positive momentum, and ushered the grouping into a new stage of high-quality development with greater BRICS cooperation.

BRICS has become a major force for advancing a multipolar world and greater democracy in international relations. The grouping's growing influence is reflected in its expansion to 11 member countries and 10 partner countries, and in its economic and demographic scale. BRICS countries now account for approximately 40 percent of global GDP at purchasing power parity and nearly half of the world's population.

With the countercurrents of unilateralism and power politics surging, multilateralism and the international order are coming under strain, and the deficits in peace, development, security and governance continue to widen. That should further inspire the BRICS countries to stand firmly on the right side of history, strive to be pioneers of the times, steer the international order toward greater justice and equity, and work together to build a community with a shared future for humanity.

To that end, Xi called on BRICS to be a pioneer in pursuing innovation-driven development, upholding peace and stability, facilitating mutual learning between civilizations, and reforming and improving global governance.

Putting those proposals into action will help BRICS countries firmly seize the initiative in shaping their future. This will enable them to uphold a vision of common, comprehensive, cooperative and sustainable security, and play a constructive role in resolving hot spot issues by addressing both symptoms and root causes. It will also help them promote a fairer and more equitable global governance system.

Xi also proposed an initiative to promote new industrialization through artificial intelligence among BRICS countries, and said that China is willing to work with all parties to deliver more outcomes in research, development and application, and deepen cooperation in industrial and supply chains.

Xi also advocated efforts to deepen cooperation in culture, tourism and education, strengthen youth exchanges and promote more frequent interactions and closer bonds among the peoples.

These all represent concrete actions in China's commitment to advancing BRICS development and playing an active role.

Urging the group to deepen mutual understanding through communication and dialogue, Xi said that the BRICS countries should remain sincere and candid with one another, seek common ground while respecting differences, and respect each other's core concerns.

Over an extraordinary two-decade journey, solidarity and cooperation have remained the driving force behind the BRICS cause, Xi stressed.

China will take over as the rotating chair of BRICS and host its 19th summit next year, and the Chinese side stands ready to work with all parties to build consensus, create a better future and embark on BRICS' third "golden decade", jointly opening up a bright future of prosperity and progress.

The leaders attending the summit reached a common understanding across a range of important areas, including security, cooperation and development, and adopted a joint declaration on Saturday. This demonstrates BRICS countries' clear-eyed assessment of the opportunities and challenges they face, as well as their shared willingness to build greater consensus on issues of common concern. This will help create favorable conditions for China, as the next rotating chair, to steer BRICS toward even greater development in the next stage.

SOURCE China Daily

Share this article